NVO vs. NTLA
NVO (Novo Nordisk A/S) and NTLA (Intellia Therapeutics, Inc.) are both stocks. Both are in the Healthcare sector — NVO in Drug Manufacturers - General, NTLA in Biotechnology. Over the past 10 years, NVO returned 7.56%/yr vs -7.62%/yr for NTLA. At a 0.23 correlation, their price movements are largely independent.
Performance
NVO vs. NTLA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, NVO achieves a -10.74% return, which is significantly lower than NTLA's 34.71% return. Over the past 10 years, NVO has outperformed NTLA with an annualized return of 7.56%, while NTLA has yielded a comparatively lower -7.62% annualized return.
NVO
- 1D
- -0.18%
- 1M
- -1.92%
- YTD
- -10.74%
- 6M
- -9.50%
- 1Y
- -42.47%
- 3Y*
- -15.59%
- 5Y*
- 2.92%
- 10Y*
- 7.56%
NTLA
- 1D
- -1.94%
- 1M
- -7.49%
- YTD
- 34.71%
- 6M
- 34.26%
- 1Y
- 45.73%
- 3Y*
- -35.92%
- 5Y*
- -32.32%
- 10Y*
- -7.62%
NVO vs. NTLA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
NVO Novo Nordisk A/S | -10.74% | -39.22% | -15.93% | 54.84% | 22.66% | 63.52% | 23.33% | 28.70% | -12.98% | 52.92% |
NTLA Intellia Therapeutics, Inc. | 34.71% | -22.90% | -61.76% | -12.61% | -70.49% | 117.35% | 270.82% | 7.47% | -28.98% | 46.61% |
Correlation
The correlation between NVO and NTLA is 0.33, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.33 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.23 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.22 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.23 |
Correlation (All Time) Calculated using the full available price history since May 6, 2016 | 0.23 |
The correlation between NVO and NTLA shifts across timeframes, from 0.22 (5 years) to 0.33 (1 year), reflecting how their relationship changes across market environments.
Fundamentals
NVO:
$195.21B
NTLA:
$1.43B
NVO:
DKK 27.42
NTLA:
-$3.58
NVO:
3.85
NTLA:
20.19
NVO:
6.21
NTLA:
2.31
NVO:
DKK 327.80B
NTLA:
$66.09M
NVO:
DKK 268.30B
NTLA:
-$33.92M
NVO:
DKK 181.54B
NTLA:
-$299.32M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NVO vs. NTLA — Risk / Return Rank
NVO
NTLA
NVO vs. NTLA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Novo Nordisk A/S (NVO) and Intellia Therapeutics, Inc. (NTLA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NVO | NTLA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.31 | ||
| Sortino ratioReturn per unit of downside risk | -2.32 | ||
| Omega ratioGain probability vs. loss probability | 0.85 | 1.18 | -0.33 |
| Calmar ratioReturn relative to maximum drawdown | -0.80 | 0.63 | -1.43 |
| Martin ratioReturn relative to average drawdown | -1.18 | 0.99 | -2.17 |
Loading charts...
Drawdowns
NVO vs. NTLA - Drawdown Comparison
The maximum NVO drawdown since its inception was -74.70%, smaller than the maximum NTLA drawdown of -96.45%. Use the drawdown chart below to compare losses from any high point for NVO and NTLA.
Loading charts...
Drawdown Indicators
| NVO | NTLA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -74.70% | -96.45% | +21.75% |
Max Drawdown (1Y)Largest decline over 1 year | -54.34% | -71.27% | +16.93% |
Max Drawdown (3Y)Largest decline over 3 years | -74.70% | -86.28% | +11.58% |
Max Drawdown (5Y)Largest decline over 5 years | -74.70% | -96.45% | +21.75% |
Max Drawdown (10Y)Largest decline over 10 years | -74.70% | -96.45% | +21.75% |
Current DrawdownCurrent decline from peak | -68.11% | -93.15% | +25.04% |
Average DrawdownAverage peak-to-trough decline | -17.79% | -57.11% | +39.32% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 37.62% | 45.80% | -8.18% |
Volatility
NVO vs. NTLA - Volatility Comparison
The current volatility for Novo Nordisk A/S (NVO) is 10.68%, while Intellia Therapeutics, Inc. (NTLA) has a volatility of 24.01%. This indicates that NVO experiences smaller price fluctuations and is considered to be less risky than NTLA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NVO | NTLA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 10.68% | 24.01% | -13.33% |
Volatility (6M)Calculated over the trailing 6-month period | 38.04% | 54.68% | -16.64% |
Volatility (1Y)Calculated over the trailing 1-year period | 51.88% | 96.60% | -44.72% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 38.33% | 80.85% | -42.52% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 32.56% | 78.41% | -45.85% |
Dividends
NVO vs. NTLA - Dividend Comparison
NVO's dividend yield for the trailing twelve months is around 4.11%, while NTLA has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NTLA Intellia Therapeutics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
NVO Novo Nordisk A/S | 4.11% | 3.31% | 1.68% | 1.00% | 1.20% | 1.35% | 1.87% | 2.14% | 1.45% | 1.52% | 2.87% | 0.92% |
Financials
NVO vs. NTLA - Financials Comparison
This section allows you to compare key financial metrics between Novo Nordisk A/S and Intellia Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
NVO and NTLA have a correlation of 0.33, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NTLA has higher volatility (24.01%) compared to NVO (10.68%). In terms of maximum drawdown, NVO dropped -74.70% vs NTLA's -96.45%.
NTLA currently has the higher Sharpe Ratio (0.47 vs -0.84), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for NVO and NTLA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer